

C-Path's TRxA Announces 2025 Request for Proposals from Academic Investigators

New Funding Opportunity for Drug Development Projects

TUCSON, Ariz., January 14, 2025 – Critical Path Institute's® (C-Path) [Translational Therapeutics Accelerator](#) (TRxA) today officially launched its 2025 global Request for Proposals for Bridging Research and Innovation in Drug Development Grants, also known as BRIDGe.

These awards aim to empower academic researchers by providing financial support and strategic guidance needed to overcome the “valley of death” in drug development, enabling the transition of innovative therapeutics from the lab to patients.

Maaïke Everts, Ph.D., Executive Director of C-Path's TRxA, expressed her enthusiasm for this next cycle of awards, stating, “The impactful progress in our currently-funded projects serves as a testament to the power of collaboration in drug discovery and development; we look forward to identifying the exceptional projects that will emerge from this cycle and, together, shaping the next generation of life changing medicines.”

As a nonprofit drug accelerator, TRxA offers selected BRIDGe awardees a comprehensive suite of resources, including:

- Funding to advance drug development initiatives.
- Strategic and tactical expertise in drug discovery and development, including regulatory science considerations.
- Resources and hands-on guidance, collaborating closely with academic researchers to develop comprehensive data packages for potential drug candidates, a key to garnering interest from biotechnology and pharmaceutical companies to invest in clinical trials.

For this RFP, eligible platforms include small molecules, protein-based therapeutics, and in vivo gene-based therapies.

TRxA is accepting applications for projects in the following therapeutic areas:

- Brain health
- Pediatrics
- Rare and orphan diseases



More information about this funding opportunity is available in [TRxA's Guidance Document for Applicants](#). Also, to assist applicants, TRxA will host a [2025 TRxA Funding Opportunities webinar at 10 a.m. ET, Tuesday, January 28](#). Registration is required for this no-cost event. The webinar will provide an overview of the types of projects TRxA funds, eligibility criteria for TRxA awards, details about how to apply before the first submission deadline of March 19, 2025, and a live Q&A.

To learn more, visit c-path.org/programs/trxa or email TRxA at trxa@c-path.org.

About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the [FDA's Critical Path Initiative](#), Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. **C-Path's mission is to lead collaborations that advance better treatments for people worldwide.** Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org
